Navigation Links
EntreMed Reports Fourth Quarter and Year-End 2011 Financial Results

ete with larger, better financed biotechnology companies that may develop new approaches to the treatment of our targeted diseases or develop product candidates more advanced than ENMD-2076.  Such factors, among others, could have a material adverse effect upon our business, results of operations and financial condition.  We caution readers not to place undue reliance on any forward-looking statements, which only speak as of the date made. Additional information about the factors and risks that could affect our business, financial condition and results of operations, are contained in our filings with the SEC, which are available at

Investor Relations
EntreMed, Inc.
240.864.2643 Table Attached)ENTREMED, INC.SUMMARY OF OPERATING RESULTSThree Months EndedDecember 31,(in millions)2011

2010Total revenues

$ 1,932,035

$ 3,693,167Research and development

$ 405,936

$ 1,683,141General and administrative

$   521,906

$   884,339Net income


$1,064,926Dividend on Series A convertible preferred stock

$ (251,250)

$   (251,250)Net income attributable to common shareholders

$   753,272

$   813,676Net income per share attributable tocommon shareholders (basic and diluted)


.07Weighted average number of shares outstanding (basic and diluted)


11,401,749Twelve Months EndedDecember 31,2011

2010Total revenues


3,693,167Research and development


4,829,943General and administrative

$   3,051,511

$   3,397,866Acquired in-process R&D


$   3,000,000Net loss

$   (4,558,495)


SOURCE EntreMed, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. EntreMeds ENMD-2076 Demonstrates Clinical Activity in Recurrent, Platinum-Resistant Ovarian Cancer Patients
2. EntreMed Reports Fourth Quarter and Year-End 2010 Financial Results
3. EntreMed Reports Receipt of Third Quarter Royalty Payment
4. EntreMed ENMD-2076 Phase 1 Data to Be Presented at ASCO Annual Meeting
5. EntreMed Initiates ENMD-2076 Clinical Trial in Multiple Myeloma
6. EntreMed to Present at the New York Society of Security Analysts Industry Conference
7. EntreMeds MKC-1 Meets Primary Efficacy Endpoint in Non-Small Cell Lung Cancer Clinical Trial
8. EntreMed Reports Third Quarter 2008 Financial Results
9. EntreMeds ENMD-2076 Demonstrates Tumor Regression in Human Colon Cancer Model
10. EntreMed to Present at BioPartnering Europe Conference
11. EntreMed Announces Stock Listing Transfer to Nasdaq Capital Market
Post Your Comments:
(Date:10/9/2015)... ... October 09, 2015 , ... ... current methods of separating those cells from their surroundings for research, diagnostics, and ... cells. , To address this, Ann Arbor-based startup Akadeum Life Sciences ...
(Date:10/8/2015)... , Oct. 8, 2015   Intrexon Corporation ... today announced the appointment of Joseph L. Vaillancourt ... succeeding Nir Nimrodi who continues in his ... direct Intrexon,s endeavors to generate sustainable, biologically based solutions ... , where he held a variety of key roles ...
(Date:10/8/2015)... Oct. 8, 2015  ATCC, the premier global biological ... has been selected by The Michael J. Fox Foundation ... to academic, pharmaceutical, and biotechnology organizations committed to speed ... the United States , and more than 5 ... the United States , and more than 5 ...
(Date:10/8/2015)... , October 8, 2015 ... .   --> Goldman Small Cap ... the small cap and microcap sectors, announced today ... report on PharmaCyte Biotech, Inc. (OTCQB - PMCB), ... on developing and preparing treatments for cancer and ...
Breaking Biology Technology:
... BRUSSELS, December 14 , - Results ... Seven Major Industrialized Countries , , - A third of women ... enjoyment of the festive season, - Women living with rheumatoid arthritis ... and wrapping presents most, difficult to do, ...
... (12/11/2009) Boston College researchers have observed the "hot electron" ... successfully harvested the elusive charges using ultra-thin solar cells, opening ... report in the current online edition of Applied Physics ... it generates free electrons in a range of energy states. ...
... , CALGARY, Dec. 11 /PRNewswire-FirstCall/ - Oncolytics Biotech ... today announced the appointment of Dr. Alan Warrander to ... Business Development. , "Dr. Warrander will be responsible for ... said Dr. Brad Thompson, President and CEO of Oncolytics. ...
Cached Biology Technology:
(Date:9/10/2015)... , Sept. 10, 2015 Report ... New Study Reveals Selling Opportunities and Revenue Prospects ... the future of biologics, especially new drug classes? ... will stay ahead with exclusive market data and ... explore trends, developments, results, opportunities and sales predictions. ...
(Date:9/10/2015)... 10, 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ... on the growing mobile commerce market, announces that the ... Touch of Modern, will feature the Wocket® smart wallet ... . Touch Of Modern is ... lifestyle products to its 7.2 million members. Customers are ...
(Date:9/8/2015)... 8, 2015  Affectiva, global leader in emotion-sensing ... Service, a new data solution, and version 2.0 ... Affectiva,s highly accurate and patented science, these new ... to transform industries such as market research, gaming, ... experience, online education, HR, automotive, robotics, healthcare and ...
Breaking Biology News(10 mins):
... The most widely adopted measure for assessing the state ... in nearly half the ecosystems where it was applied. ... fisheries scientists, and is reported in this week,s issue of ... it,s like flipping a coin; half the time you get ...
... are reporting the first direct evidence that a subtle ... affect its function. The finding has immediate implications for ... could offer insight into such conditions as osteoporosis, arthritis, ... scientists discovered that blocking the function of a particular ...
... PROVIDENCE, R.I. [Brown University] One of biggest factors promoting ... water flows, according to new research by ecologists at Brown ... that the faster the flow, the greater the number of ... The findings, published the week of Nov. 15 in the ...
Cached Biology News:
Full-length cDNA clone CS0DJ013YG01 of T cells (Jurkat cell line) of Homo sapiens (human). [Source:Uniprot/SPTREMBL;Acc:Q86SZ3] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Biology Products: